Most Recent
A judge has approved a $1 million penalty against Queensland crane company NQ Cranes for engaging in a conspiracy with a multinational rival to divide the Brisbane and Newcastle markets.
In one of the year's biggest class action settlements, PTTEP Australasia has agreed to pay $192.5 million to settle a representative action over a 2009 oil spill that affected 15,000 Indonesian seaweed farmers.
The law firm that filed a second securities class action against failed Blue Sky Alternative Investments and auditor EY has moved swiftly to stay a competing class action brought three months ago.
Avant Insurance has lost its bid to challenge a ruling which put it on the hook for indemnifying a plastic surgeon in class action proceedings over allegedly botched breast augmentations at a defunct NSW clinic.
The High Court has agreed to hear prosecutors' appeal of a "manifestly inadequate" $1.35 million penalty against an engineering firm for bribing foreign officials in Vietnam to secure $10 million in infrastructure contracts.
The High Court has turned down the appeal of the former Blue Star Helium CEO who was hit with a $40,000 penalty and four-year ban after the company failed to disclose to shareholders the identity of the buyer behind a botched sale of Texas oil assets.
A former Tesla Motors Australia director has pleaded guilty to two counts of insider trading for acquiring shares in Piedmont Lithium based on insider information he had about an in-principle agreement the mining company had to supply lithium to Tesla.
Medibank is facing another class action investigation over a massive data breach that left the personal information of almost 10 million customers exposed, just days after criminals began publishing sensitive customer health data.
A class action against KPMG over the failure of six managed investment schemes for eucalyptus wood in Tasmania can't add new claims against the accounting firm three months out from trial.
Novartis and and generic drug maker Pharmacor have resolved litigation over the Swiss pharmaceutical giant's patents for blockbuster MS drug Gilenya.